Clinical trial
A Phase 2, Randomized, Observer-blind, Single Center, Dose-Ranging Study to Evaluate the Immunogenicity Safety and Tolerability of the H5 VLP Influenza Vaccine With or Without Alhydrogel in Healthy Adults 18-60 Years of Age.
NCT01244867 is registered in ClinicalTrials.gov with Medicago as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Observer-blind, Single Center, Dose-Ranging Study to Evaluate the Immunogenicity Safety and Tolerability of the H5 VLP Influenza Vaccine With or Without Alhydrogel in Healthy Adults 18-60 Years of Age.
- Lead sponsor
- Medicago
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2010
- Completion date
- September 30, 2011
- Enrollment
- 255 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.